Navigation Links
Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
Date:6/10/2008

William Bailey, M.D., lead author and Director of the Lung Health Center at the University of Alabama at Birmingham. "Preventing exacerbations and improving lung function are important goals of asthma management."

Current treatment guidelines recommend the addition of a LABA to an ICS in patients with moderate to severe asthma who are uncontrolled on an ICS alone. Taken in combination, an ICS and LABA fight the two main components of asthma -- inflammation (swelling in the airways) and airway constriction (the tightening of muscles that surround the airways). Inhaled corticosteroids treat the inflammation, while LABAs treat the airway constriction. Optimal therapy for many patients with persistent moderate to severe asthma requires treatment of both these components.

The study was designed to primarily show that Advair improved the rate of exacerbations compared to Flovent. While Advair patients had a lower exacerbation rate than those patients in the Flovent group, the difference was not statistically significant. On most of the secondary endpoints, patients given Advair performed better than patients who used Flovent. Forced expiratory volume in one second (FEV1) improved in Advair patients. Both morning and evening peak expiratory flow (PEF) were also improved in the Advair group. Patients using Advair were also less likely to awake at night due to asthma-related breathing difficulties. Additionally, the Advair group showed reductions in the rate of daily symptoms and the need for a rescue inhaler.

Both Advair and Flovent were well tolerated. Over a one-year period, the overall incidence of adverse events was similar between the two groups.

Important Information about Advair Diskus

Advair Diskus won't replace fast-acting inhalers for sudden symptoms and should not be taken more than twice a day. Advair Diskus contains salmeterol. In patients with asthma, medicines like salmeterol may increase the chance of asthma-related death.
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, today ... 28, 2015. Net sales for the first ... 1.4% compared with the first quarter of 2014.  This ... 6.0% decline related to foreign currency exchange.  In local ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9Henry Schein Reports Record First Quarter Results 10Henry Schein Reports Record First Quarter Results 11Henry Schein Reports Record First Quarter Results 12Henry Schein Reports Record First Quarter Results 13Henry Schein Reports Record First Quarter Results 14Henry Schein Reports Record First Quarter Results 15Henry Schein Reports Record First Quarter Results 16Henry Schein Reports Record First Quarter Results 17
... 04, 2007 /PRNewswire/ -- GlaxoSmithKline today,announced results ... in,advanced or metastatic renal cell carcinoma (RCC), ... trials were presented at the,43rd Annual Meeting ... in Chicago. The results observed in these ...
... Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESS,NEWSWIRE) -- ... historic landmark in medical oncology and a,definitive benchmark ... first clinical report of its kind, Le Morte ... the International Journal of,Oncology, Vol.30, pp. 1297-1307 -- ...
Cached Medicine Technology:GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 5GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 6GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 7News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 2News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 3
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... Morganville, NJ (PRWEB) May 04, 2015 ... that he has been chosen to receive the America’s ... Board. Dr. Champagne’s selection as a top dentist ... his commitment to continuing education and his compassion for ... Board selects professionals who exemplify excellence in their field. ...
(Date:5/4/2015)... For partners who’d like to become parents, ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional lubricants ... Astroglide TTC™ is specially formulated to provide a better ... for Disease Control, an average of one in ... a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... The Accreditation for Cardiovascular ... congenital heart disease (CHD) standards for Pediatric ... Driven by the latest available clinical evidence, ... of interventional procedures in pediatric patients and ... ACE CHD Standards for PCCL Accreditation, like ...
(Date:5/4/2015)... May 04, 2015 Sara Soulati, CEO ... practice management firm in Los Angeles associated with the ... patent-pending status of The Sara Soulati Health For Life ... 2010, is a lifestyle modification and disease prevention program. ... to the U. S. Patents and Trademarks Office and ...
Breaking Medicine News(10 mins):Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... are a valuable tool for controlling infectious diseases ... Routine immunizations and supplemental immunization activities, such as ... to entire populations. Current measurements used to determine ... flawed and inconsistent. According to a new study ...
... announces a partnership with the U.S. Food and Drug ... Center of Excellence in Regulatory Science and Innovation (CERSI). ... an initial $1 million grant, which is potentially part ... and manufacturing. Experts in science, medicine ...
... more rapid innovation in science and technology, Peter Thiel ... Breakout Labs. Speaking at Stanford to an event ... Thiel announced that Breakout Labs will use a revolving ... research is funded by helping independent scientists and early-stage ...
... building blocks of proteins, are essential to support the ... An insufficient supply of amino acids in the mother,s ... developmental abnormalities and complications of pregnancy that result in ... cutting-edge article in the peer-reviewed journal Cellular Reprogramming ...
... , WEDNESDAY, Oct. 26 (HealthDay News) -- People ... attempt to boost their social status, a new study suggests. ... portions with higher social standing. For example, study participants believed ... social status than those who chose a medium or small ...
... New research has the potential to revolutionize the treatment ... a million Canadians which is expected to strike even more ... AF is the most common type of heart arrhythmia ... greater risk for stroke. Now, there is a new drug ...
Cached Medicine News:Health News:Researchers develop method to better estimate vaccine coverage 2Health News:FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation 2Health News:FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation 3Health News:Peter Thiel announces Breakout Labs to energize innovation 2Health News:Inadequate supply of protein building blocks may explain pregnancy failures in bovine cloning experiments 2Health News:Larger Food Portions May Be Seen as Status Symbols 2Health News:ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation 2Health News:ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation 3
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This is a single-action instrument that features a spring handle....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: